-

GE HealthCare announces cash dividend for third quarter of 2024

CHICAGO--(BUSINESS WIRE)--The Board of Directors of GE HealthCare Technologies Inc. (Nasdaq: GEHC) today declared a cash dividend of $0.03 per share of Common Stock for the third quarter of 2024 payable on November 15, 2024 to all shareholders of record as of October 18, 2024.

About GE HealthCare Technologies Inc.

GE HealthCare is a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator, dedicated to providing integrated solutions, services, and data analytics to make hospitals more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 125 years, GE HealthCare is advancing personalized, connected, and compassionate care, while simplifying the patient’s journey across the care pathway. Together our Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics businesses help improve patient care from diagnosis, to therapy, to monitoring. We are a $19.6 billion business with approximately 51,000 colleagues working to create a world where healthcare has no limits.

Follow us on LinkedIn, X , Facebook, Instagram, and Insights for the latest news, or visit our website https://www.gehealthcare.com/ for more information.

Contacts

Investor Relations Contact:
Carolynne Borders
+1 631 662 4317
carolynne.borders@gehealthcare.com

Media Contact:
Jennifer Fox
+ 1 414 530 3027
jennifer.r.fox@gehealthcare.com

GE HealthCare Technologies Inc.

NASDAQ:GEHC

Release Versions

Contacts

Investor Relations Contact:
Carolynne Borders
+1 631 662 4317
carolynne.borders@gehealthcare.com

Media Contact:
Jennifer Fox
+ 1 414 530 3027
jennifer.r.fox@gehealthcare.com

More News From GE HealthCare Technologies Inc.

ESTRO 2026 Congress: GE HealthCare to spotlight AI-enabled solutions to advance precision care across radiation therapy and image-guided interventions

CHICAGO--(BUSINESS WIRE)--At the European Society for Radiotherapy and Oncology (ESTRO) 2026 Congress in Stockholm, GE HealthCare (Nasdaq: GEHC) will highlight a portfolio of AI-enabled solutions designed to support clinicians across radiation therapy, theranostics, and image-guided interventions. The company’s presence underscores its focus on reducing workflow complexity, improving coordination across departments, and enabling more timely and personalized cancer care. According to the World H...

GE HealthCare next-gen SIGNA MR technology helps advance research discovery and translate innovation into clinical impact

CHICAGO--(BUSINESS WIRE)--As the global magnetic resonance (MR) community convenes for the International Society for Magnetic Resonance in Medicine (ISMRM) 2026 Annual Meeting, GE HealthCare (Nasdaq: GEHC) today announced advancements in research tools and MR systems that aim to accelerate discovery, strengthen collaboration across research programs, and turn innovation into meaningful clinical achievements. GE HealthCare continues to invest in advanced MR technology with its next-generation SI...

GE HealthCare announces executive team and operational updates to enhance execution, accelerate innovation, and drive growth

CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) announced today a strategic evolution to its operations and executive leadership team to help shape the company’s next chapter of growth and better serve patients and customers globally. The changes will also position the company to enhance execution, accelerate innovation, and create efficiencies. These changes are effective immediately. Phil Rackliffe has been appointed President and Chief Executive Officer of Advanced Imaging Solutions (...
Back to Newsroom